Program Announcement

for the

Department of Defense
Defense Health Program
Congressionally Directed Medical Research Programs

Multiple Sclerosis Research Program
Pilot Clinical Trial Award

Funding Opportunity Number: W81XWH-15-MSRP-PCTA
Catalog of Federal Domestic Assistance Number: 12.420

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Deadline: 5:00 p.m. Eastern time (ET), June 4, 2015
- Invitation to Submit an Application: July, 2015
- Application Submission Deadline: 11:59 p.m. ET, September 10, 2015
- End of Application Verification Period: 5:00 p.m. ET, September 15, 2015
- Peer Review: November 2015
- Programmatic Review: January 2016

The CDMRP eReceipt System has been replaced with the electronic Biomedical Research Application Portal (eBRAP). Principal Investigators and organizational representatives should register in eBRAP as soon as possible. All pre-applications must be submitted through eBRAP. In addition, applications submitted through Grants.gov will now be available for viewing, modification, and verification in eBRAP prior to the end of the application verification period.

This Program Announcement/Funding Opportunity is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.
TABLE OF CONTENTS

I. Funding Opportunity Description ........................................................................ 3
   A. Program Description ....................................................................................... 3
   B. FY15 MSRP Focus Areas ................................................................................ 3
   C. Award Information ......................................................................................... 3
   D. Eligibility Information .................................................................................... 5
   E. Funding ............................................................................................................ 5

II. Submission Information ....................................................................................... 7
   A. Where to Obtain the Grants.gov Application Package ..................................... 7
   B. Pre-Application Submission Content ............................................................... 8
   C. Full Application Submission Content ............................................................. 10
   D. Applicant Verification of Grants.gov Submission in eBRAP ............................. 16
   E. Submission Dates and Times ......................................................................... 17
   F. Other Submission Requirements .................................................................... 17

III. Application Review Information ........................................................................ 17
   A. Application Review and Selection Process ..................................................... 17
   B. Application Review Process ......................................................................... 18
   C. Recipient Qualification .................................................................................. 19
   D. Application Review Dates ............................................................................ 19
   E. Notification of Application Review Results .................................................... 19

IV. Administrative Actions ...................................................................................... 19
   A. Rejection ......................................................................................................... 20
   B. Modification .................................................................................................... 20
   C. Withdrawal ..................................................................................................... 20
   D. Withhold ......................................................................................................... 21

V. Award Administration Information ..................................................................... 21
   A. Award Notice .................................................................................................. 21
   B. Administrative Requirements ........................................................................ 21
   C. National Policy Requirements ...................................................................... 21
   D. Reporting ........................................................................................................ 21
   E. Award Transfers ............................................................................................. 22

VI. Agency Contacts ............................................................................................... 22
   A. CDMRP Help Desk ....................................................................................... 22
   B. Grants.gov Contact Center ........................................................................... 22

VII. Application Submission Checklist .................................................................... 23
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

Applications to the Fiscal Year 2015 (FY15) Multiple Sclerosis Research Program (MSRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The executing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP). The MSRP, established in FY09, is dedicated to supporting pioneering concepts and high impact research that are relevant to the prevention, etiology, pathogenesis, assessment, and treatment of MS to ultimately lessen its personal and societal impact. Appropriations for the MSRP from FY09 through FY14 totaled $28.1 million (M). The FY15 appropriation is $5M.

B. FY15 MSRP Focus Areas

All applications for the FY15 MSRP funding opportunities are expected to address at least one of the following aspects of MS symptoms: Pathophysiology, Measurement, and Treatment/Patient Care. Symptoms may include pain, fatigue, cognitive dysfunction, visual impairment, motor impairment, impaired mobility, loss of bladder control, and sexual dysfunction.

To be considered for funding, proposed projects must address at least one of the following:

- Development of technology to measure symptoms
- Outcome measure development and/or validation
- Rehabilitation
- Mechanisms underlying pathophysiology
- Studies of symptomatic interventions
- Observational studies on the prevalence or significance of symptoms

Projects addressing the following will not be considered for funding:

- Studies of disease-modifying therapies that secondarily impact symptoms
- Regenerative therapies

C. Award Information

The MSRP Pilot Clinical Trial Award (PCTA) mechanism is being offered for the first time in FY15.

The PCTA supports early-phase, proof-of-principle clinical trials to investigate hypothesis-based, innovative interventions that have the potential to result in a profound impact on
management of MS symptoms. While therapeutic approaches proposed for testing through the PCTA must represent novel, hypothesis-based, “outside-the-box” approaches for treating MS symptoms, they may include therapies already in clinical use, or undergoing clinical testing, for other diseases, provided that the proposed use for MS would lead to a major advancement for treating one of the disease symptoms. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform MS patient care.

The PCTA will support clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drugs or drug combinations, Class II or III for devices, or other types of trials that conduct early clinical testing of innovative approaches for MS symptoms. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking funding for a preclinical research project should consider the Investigator-Initiated Research Award (W81XWH-15-MSRP-IIRA). The term “human subjects” is used in this Program Announcement/Funding Opportunity to refer to individuals who will be recruited for or who will participate in the proposed pilot clinical trial. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program

Examples of acceptable studies include but are not limited to the following:

- Identification of an appropriate population for the proposed study
- Identification of the dosage, duration, and/or delivery strategy of an intervention
- Evaluation of the feasibility of the intervention in MS
- Evaluation of efficacy and safety

The following are important aspects of submission for the PCTA:

- Pre-application is required; application submission is by invitation only.
- The application must include scientific rationale and/or preliminary data relevant to MS and the proposed study.
- The proposed intervention to be tested should offer significant potential impact on the management of MS symptoms.
- The application should demonstrate documented availability of, and access to, a suitable patient population that will support a meaningful outcome for the study.
- The application should clearly describe the steps that will be taken to advance the intervention into the next stage of development following the conclusion of this award.
- Preclinical studies will not be supported by this mechanism.
- Investigational New Drug (IND) or Investigational Device Exemption (IDE) approvals, if applicable, must be in place before an award will be made.
- Clinical trials are expected to be initiated within 6 months of the award date.
Funding from the PCTA must support a clinical trial and cannot be used for preclinical research or correlative studies. Principal Investigators (PIs) seeking funding for preclinical or correlative studies should refer to the FY15 MSRP Investigator-Initiated Research Award mechanism (Funding Opportunity Number: W81XWH-15-MSRP-IIRA).

**Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers:** All Department of Defense (DoD)-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO), in addition to the local Institutional Review Board (IRB) of record. Local IRB approval at the time of submission is not required. The HRPO is mandated to comply with specific laws and requirements governing all research involving human anatomical substances, human subjects, or human cadavers that is supported by the DoD. These laws and requirements will necessitate information in addition to that supplied to the IRB. *Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes.* The HRPO reviews and approves the participation of each site in the clinical trial. Refer to the General Application Instructions, Appendix 5, and the Human Subject Resource Document available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.

The CDMRP intends that information, data, and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 3, Section L.

**D. Eligibility Information**

- PIs at or above the level of Assistant Professor (or equivalent) are eligible to submit applications.
- Cost sharing/matching is not an eligibility requirement.
- Eligible investigators must apply through an organization. Organizations eligible to apply include national, international, for-profit, nonprofit, public, and private organizations.
- Refer to the General Application Instructions, Appendix 1, for general eligibility information.

**E. Funding**

Applications with a single Principal Investigator (PI):

- The maximum period of performance is 3 years.
- The anticipated direct costs budgeted for the entire period of performance will not exceed $600,000. Associated indirect costs can be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $600,000 direct costs or using an indirect rate exceeding the organization’s negotiated rate.
• All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

• The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

Refer to the General Application Instructions, Section II.C.5., for budget regulations and instructions for the Research & Related Budget. For all Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in Section II.C.5. of the General Application Instructions.

For this award mechanism, direct costs may be requested for (not all-inclusive):

• Salary
• Research supplies
• Equipment
• Research-related subject costs
• Clinical research costs
• Travel between collaborating organizations
• Travel costs to attend scientific/technical meetings

Shall not be requested for:

• Preclinical research studies

Intramural (DoD), other Federal agency, and extramural investigators are encouraged to apply to this Program Announcement/Funding Opportunity. An intramural investigator is defined as a DoD military or civilian employee working within a DoD laboratory or medical treatment facility, or working in a DoD activity embedded within a civilian medical center. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective resource managers. It is permissible for an intramural investigator to be named as a collaborator on an application submitted by an extramural investigator. In such cases, the extramural investigator must include a letter from the intramural collaborator’s Commander or Commanding Officer that authorizes the involvement of the intramural collaborator.

As required of all applicants to this Program Announcement/Funding Opportunity, if PIs from Federal agencies submit applications, they must submit through Grants.gov. Therefore, Federal applicants must be familiar with Grants.gov requirements, including the need for an active System for Award Management (SAM) registration and a Data Universal Numbering System (DUNS) number. Refer to Section II.A. of the General Application Instructions for further information regarding Grants.gov requirements.

Awards to extramural organizations will consist solely of assistance agreements (Cooperative Agreements and Grants). Awards to intramural agencies and other Federal agencies may be executed through a direct fund transfer (e.g., the Military Interdepartmental Purchase Request
[MIPR] or Funding Authorization Document [FAD] process). Direct transfer of funds from the recipient to a Federal agency is not allowed except under very limited circumstances. Refer to the General Application Instructions, Section II.C.5. Research & Related Budget, for additional information on budget considerations for applications involving Federal agencies.

*The CDMRP expects to allot approximately $2.9M of the $5M FY15 appropriation to fund approximately three Pilot Clinical Trial Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program.*

**II. SUBMISSION INFORMATION**

Submission is a two-step process requiring both (1) pre-application submission through the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org/) and (2) application submission through Grants.gov (http://www.grants.gov/). Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov.

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements, and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.

PIs should ensure that their name and email address are the same as the name and email address that will be provided on the SF-424 Form of the Grants.gov application package submitted to Grants.gov. The organization, Business Officials, PI(s), and eBRAP log number named in the full application submitted to Grants.gov must match those named in the pre-application in eBRAP. Application viewing, modification, and verification in eBRAP is strongly recommended, but not required. The Project Narrative and Budget cannot be changed after the application submission deadline. Any other application component cannot be changed after the end of the application verification period.

**A. Where to Obtain the Grants.gov Application Package**

To obtain the Grants.gov application package, including all required forms, perform a basic search using the Funding Opportunity Number W81XWH-15-MSRP-PCTA in Grants.gov (http://www.grants.gov/).
B. Pre-Application Submission Content

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

A change in PI or organization after submission of the pre-application may be allowed after review of a submitted written appeal (contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507) and at the discretion of the USAMRAA Grants Officer.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

- **Application Information – Tab 1**
- **Application Contacts – Tab 2**
  - Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF-424 Form). The Business Official must either be selected from the eBRAP list or invited in order for the pre-application to be submitted.
  - It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.
- **Collaborators and Key Personnel – Tab 3**
  - Enter the name, organization, and role of all collaborators and key personnel associated with the application.
  - FY15 MSRP Integration Panel (IP) members should not be involved in any pre-application or application. For questions related to IP members and pre-applications or applications, refer to Section IV.C., Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
- **Conflicts of Interest (COIs) – Tab 4**
  - List all individuals other than collaborators and key personnel who may have a COI in the review of the application (including those with whom the PI has a personal or professional relationship).
- **Pre-Application Files – Tab 5**
  
  *Note: Upload document(s) as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.*
**Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

- **Background/Readiness:** Clearly present the ideas and reasoning behind the proposed pilot clinical trial; include relevant literature citations and preliminary studies that led to the development of the proposed pilot clinical trial. Clearly describe the intervention and its target and mechanism of action in MS. Demonstrate that there is sufficient scientific evidence to support moving into the stage of proposed research. Briefly state the qualifications of the PI and key personnel to perform the described research project.

- **Hypothesis and Approach:** Concisely state the project’s hypothesis and describe the scientific approach. Include appropriate controls and demonstrate that the work is appropriately powered.

- **Study Design:** Describe the type of proposed pilot clinical trial to be performed. The description should include:
  - The type of study to be performed (e.g., phase/class, prospective, randomized, controlled, etc.) and proposed methodology
  - The study variables and proposed measurement
  - The feasibility of initiating the pilot clinical trial within 6 months of the award date

- **Clinical Impact:** Describe how the proposed pilot clinical trial, if successful, will have a major impact (both short-term and long-term) toward improving MS treatment, patient care, and/or quality of life. Briefly describe how the proposed study is responsive to at least one of the FY15 MSRP Focus Areas.

**Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application must be uploaded as individual pdf documents and are limited to:

- **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate.

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

- **Key Personnel Biographical Sketches (five-page limit per individual).**

- **Submit Pre-Application – Tab 6**
  - This tab must be completed for the pre-application to be accepted and processed.
Pre-Application Screening

- Pre-Application Screening Criteria

To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the MSRP, pre-applications will be screened based on the following criteria:

  - **Clinical Impact:** To what extent the potential short- and long-range outcome(s) of the proposed pilot clinical trial, if successful, will produce results that are likely to translate into improved MS treatment, patient care, and/or quality of life.

  - **Research Strategy and Feasibility:** To what extent the scientific rationale and/or preliminary data support the proposed pilot clinical trial.

  - **Personnel:** To what extent the study team’s experience, expertise, and records of accomplishment are appropriate to successfully complete the proposed pilot clinical trial (e.g., statistical expertise, expertise in the disease, and clinical studies).

- Notification of Pre-Application Screening Results

Following the pre-application screening, PI’s will be notified as to whether or not they are invited to submit full applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated on the title page of this Program Announcement/Funding Opportunity.

C. Full Application Submission Content

Applications will not be accepted unless the PI has received notification of invitation.

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed Grants.gov application package provided in Grants.gov for this Program Announcement/Funding Opportunity. The Grants.gov application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (http://www.grants.gov/).

**Note:** The Project Narrative and Budget Form cannot be changed after the application submission deadline. If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or Budget Form needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline.

**Grants.gov application package components:** For the Pilot Clinical Trial Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):
1. **SF-424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

2. **Attachments Form**

   Each attachment to the Grants.gov application forms must be uploaded as an individual PDF file in accordance with the formatting guidelines listed in Appendix 2 of the General Application Instructions. For all attachments, ensure that the file names are consistent with the guidance. Grants.gov will reject attachments with file names longer than 50 characters or incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, Grants.gov has file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB and the file size for the entire Grants.gov application package may not exceed 200 MB.

   *The Project Narrative is NOT the formal clinical trial protocol. Instead, all essential elements of the proposed clinical trial necessary for scientific review must be included as directed in Attachment 1 (the Project Narrative) and Attachments 6-8 described below. Failure to submit these attachments as part of the application package will result in rejection of the entire application.*

   - **Attachment 1: Project Narrative (10-page limit):** Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

     Describe the proposed project in detail using the outline below.

     ◦ **Background:** Describe in detail the rationale for the study. Provide a literature review and describe the preliminary studies and/or preclinical data that led to the development of the proposed pilot clinical trial. The background section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses. This section should establish the relevance of the study and explain the applicability of the proposed findings.

     *The Project Narrative must include scientific rationale and/or preliminary data relevant to MS and the proposed pilot clinical trial.*

     ◦ **Objectives/Specific Aims/Hypotheses:** Provide a description of the purpose and objectives of the proposed pilot clinical trial with detailed specific aims and/or study questions/hypotheses.

     ◦ **Research Strategy and Feasibility:** Describe the type of proposed pilot clinical trial to be performed and outline the proposed methodology in sufficient detail to show a clear course of action.
– Identify the intervention to be tested and describe the projected outcomes.
– Define the study variables, outline why they were chosen, and describe how they will be measured. Include a description of appropriate controls and the endpoints to be tested.
– Describe the method that will be used to recruit human subjects from the accessible population, including the inclusion and exclusion criteria.
– Describe the data or statistical analyses that will be performed.
– Describe methods used for sample and data collection, as appropriate.
– Describe the availability of, and access to, the drug, compound, device, and/or other materials needed, as appropriate.

○ **Transition Plan:** Describe the steps that will be taken to advance the intervention into the next stage of development following the conclusion of this award.

○ **Ethical Considerations:** Describe the process for seeking informed consent, clearly identify all study risks, and describe safety measures to minimize risks to human subjects and study personnel.

• **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. **There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested will result in the removal of those items or may result in administrative withdrawal of the application.**

  ○ **References Cited:** List the references cited (including URLs if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

  ○ **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

  ○ **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

  ○ **Publications and/or Patent Abstracts:** Include a list of relevant publication URLs and/or patent abstracts. If publications are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
○ Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement/Funding Opportunity, such as those from members of Congress, do not impact application review or funding decisions.

○ Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.

○ Availability of Intervention (if applicable): If the proposed study involves use of a commercially produced investigational drug, device, or biologic, provide a letter of commitment from the commercial entity indicating availability of the product for the duration of the study, support for the proposed phase of research, and support for the indication to be tested.

○ Intellectual Property
  - Background and Proprietary Information: All software and data first produced under the award are subject to a Federal purpose license. Provide a list of all background intellectual property to be used in the project or provide a statement that none will be used. If applicable, state and identify the proprietary information that will be provided to the Government and indicate whether the applicant will require a waiver of the Federal purpose license.
  - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

○ Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 3, Section L for more information about the CDMRP expectations for making data and research resources publicly available.


The technical abstract is used by all reviewers. Therefore, clarity and completeness within the space limits of the technical abstract are highly important.

Technical abstracts should be structured using the outline below.

○ **Background:** Present the ideas and rationale behind the proposed pilot clinical trial.

○ **Objective/Hypothesis:** State the objective/hypothesis to be tested. Provide evidence that supports the objective/hypothesis.
Specific Aims: List the specific aims.

Study Design: Briefly describe the study design including appropriate controls and endpoints, as appropriate.

Clinical Impact: Briefly describe how the proposed pilot clinical trial will lead to improved MS treatment, patient care, and/or quality of life.


The lay abstract is an important component of the application review process because it addresses issues of particular interest to the advocate community. Lay abstracts should be written using the outline below.

- Describe the objectives and rationale for the proposed pilot clinical trial in a manner that will be readily understood by readers without a background in science or medicine.
  - Do not duplicate the technical abstract.
- Describe the ultimate applicability and impact of the research.
  - What types of patients will it help, and how will it help them?
  - What are the potential clinical applications, benefits, and risks?
  - What are the likely contributions of the proposed study to advancing MS treatment, patient care, and/or quality of life?

Attachment 5: Statement of Work (SOW) (three-page limit): Upload as “SOW.pdf.” The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). For the Pilot Clinical Trial Award mechanism, use the SOW format example titled “SOW for Clinical Research (Including Trials, Special Populations).” The SOW must be in PDF format prior to attaching. Refer to the General Application Instructions, Section II.C.3., for detailed guidance on creating the SOW.

Attachment 6: Surveys, Questionnaires, and Other Data Collection Instruments, if applicable (no page limit): Upload as “Surveys.pdf.” The Surveys, Questionnaires, and Other Data Collection Instruments attachment should include a copy of the most recent version of surveys, questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information collected is related to the objectives of the study.


- Explain how the proposed pilot clinical trial addresses one or more of the FY15 MSRP Focus Areas.
○ Identify the volunteer population(s) that will participate in the proposed intervention, describe how they represent the target population that would benefit from the intervention, and describe the potential impact of the proposed pilot clinical trial on the outcomes of individuals with MS.

○ Describe the short-term impact: Detail the anticipated outcomes that will be directly attributed to the results of the proposed pilot clinical trial.

○ Describe the long-term impact: Explain the long-range vision for implementation of the intervention in the clinic or field, and describe the anticipated long-term benefits for the targeted population.

○ Describe any relevant controversies or treatment issues that will be addressed by the proposed pilot clinical trial.

○ Describe any potential issues that might limit the impact of the proposed pilot clinical trial.

○ Describe how the intervention represents an improvement over currently available interventions and/or standard of care.

• Attachment 8: IND/IDE Documentation: If submitting multiple documents, start each document on a new page. **Combine and upload as a single file named “IND-IDE.pdf.”**
  ○ Complete the IND/IDE Documentation Form, which is available for download on the Full Announcement page for this Program Announcement/Funding Opportunity on Grants.gov.

  ○ For studies requiring an IND or IDE, provide an explanation of the status of the application (e.g., past the critical 30-day period, pending response to questions raised by the Agency, on clinical hold). Provide a summary of previous meetings with the FDA on development of this product, if appropriate. A copy of the Agency meeting minutes should be included if available. Provide copies of communications from the FDA relevant to the most recent status of the IND or IDE application.

  ○ If an IND or IDE is not required for the proposed study, provide evidence in the form of communication from the FDA or the IRB of record to that effect.

• Attachment 9: Collaborating DoD Military Facility Budget Form(s), if applicable: **Upload as “MFBudget.pdf.”** If a Military Facility (military health system facility, research laboratory, treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete the Collaborating DoD Military Facility Budget Form (available for download on the eBRAP “Funding Opportunities & Forms” web page), including a budget justification, for each Military Facility as instructed. Refer to the General Application Instructions, Section II.C.8., for detailed information.
3. **Research & Related Senior/Key Person Profile (Expanded):** Refer to the General Application Instructions, Section II.C.4., for detailed information. Note: Some of the items in this attachment may be made available for programmatic review.

- **PI Biographical Sketch (five-page limit):** Upload as “Biosketch_LastName.pdf.” The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The five-page National Institutes of Health Biographical Sketch may also be used.

- **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf.”

- **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch_LastName.pdf.”

- **Key Personnel Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf.”

4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C.5., for detailed information.

- **Budget Justification (no page limit):** Upload as “BudgetJustification.pdf.” The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C.6., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C.7., for detailed information.

D. **Applicant Verification of Grants.gov Submission in eBRAP**

Prior to the end of the application verification period, PIs and organizational representatives can review and modify in eBRAP certain components of an application submitted to Grants.gov. Following retrieval and processing of the Grants.gov application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the Grants.gov application submission. eBRAP will validate retrieved files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in both the email and in the Full Application Files tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement/Funding Opportunity. **If either the Project Narrative or the budget fails eBRAP validation, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline.** The Project Narrative and Budget Form cannot be changed after the application submission deadline.
E. Submission Dates and Times

All submission dates and times are indicated on the title page of this Program Announcement/Funding Opportunity. Pre-application and application submissions are required. Failure to meet either of these deadlines will result in application rejection.

F. Other Submission Requirements

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Section II.A., for information on Grants.gov registration requirements.

III. APPLICATION REVIEW INFORMATION

A. Application Review and Selection Process

All applicants are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that makes recommendations for funding to the DHA RDA Directorate and the Office of the Assistant Secretary of Defense for Health Affairs, based on (a) technical merit and (b) the relevance to the mission of the DHP and MSRP, and to the specific intent of the award mechanism. The highest scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a nondisclosure statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with Title 18 United States Code 1905.
B. Application Review Process

1. Peer Review: To determine technical merit, all applications will be evaluated according to the following scored criteria, which are listed in decreasing order of importance:

- **Clinical Impact**
  - How well the application addresses one or more of the MSRP Focus Areas.
  - To what extent the anticipated outcomes of the proposed pilot clinical trial are relevant to individuals with multiple sclerosis.
  - How the potential outcomes of the proposed pilot clinical trial will provide/improve short-term and long-term benefits for individuals with MS.

- **Research Strategy and Feasibility**
  - How well the scientific rationale and/or the preliminary data support the proposed pilot clinical trial.
  - How well the study design supports the objective of the proposed pilot clinical trial.
  - To what extent the proposed pilot clinical trial is feasible as described.

- **Personnel**
  - To what degree the study team’s background and expertise are appropriate to accomplish the proposed work (e.g., statistical expertise, expertise in the disease, and clinical studies).
  - To what extent the levels of effort of the study team members are appropriate for successful conduct of the proposed pilot clinical trial.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Ethical Considerations**
  - How well the applicant identifies potential study risks and outlines safety steps to protect study subjects and staff.

- **Environment**
  - To what degree the scientific environment is appropriate for the proposed study.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  - To what degree the quality and extent of institutional support/commitment are appropriate for the proposed study.
  - If applicable, to what degree the intellectual and material property plan is appropriate.
• **Budget**
  ○ Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.

• **Application Presentation**
  ○ To what extent the writing, clarity, and presentation of the application components influence the review.

2. **Programmatic Review:** To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following equally considered criteria are used by programmatic reviewers:

   a. **Ratings and evaluations of the peer reviewers**
   b. **Relevance to the mission of the DHP and FY15 MSRP, as evidenced by the following:**
      • Adherence to the intent of the award mechanism
      • Program portfolio composition with consideration of the FY15 MSRP Focus Areas
      • Programmatic relevance
      • Relative impact

C. **Recipient Qualification**

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

D. **Application Review Dates**

All application review dates and times are indicated on the title page of this Program Announcement/Funding Opportunity.

E. **Notification of Application Review Results**

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

IV. **ADMINISTRATIVE ACTIONS**

After receipt of pre-applications from eBRAP or applications from Grants.gov, the following administrative actions may occur:
A. **Rejection**

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- For studies requiring an IND or IDE (Attachment 8), documentation of IND/IDE application to the FDA is missing.
- Project Narrative is missing.
- Budget is missing.

B. **Modification**

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.

C. **Withdrawal**

The following may result in administrative withdrawal of the pre-application or application:

- A FY15 MSRP IP member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY15 MSRP IP members can be found at [http://cdmrp.army.mil/msrp/panels/panels15](http://cdmrp.army.mil/msrp/panels/panels15).
- The application fails to conform to this Program Announcement/Funding Opportunity description to the extent that appropriate review cannot be conducted.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- Inclusion of any employee of CDMRP review contractors in applications for funding without adequate plans to mitigate conflicts of interest. Refer to the General Application Instructions, Section II.B., for detailed information.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
• The invited application does not propose the same research project described in the pre-
application. The proposed research is not a clinical trial.

• For studies requiring an IND or IDE, documentation of IND/IDE approval is not
submitted to the CDMRP Help Desk (help@eBRAP.org) prior to Programmatic
Review.

• An application submitted by a PI who does not meet the eligibility criteria will be
withdrawn.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from
further consideration pending institutional investigation. The institution will be required to
provide the findings of the investigation to the USAMRAA Grants Officer for a determination of
the final disposition of the application.

V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than September 30, 2016. Refer to the General Application
Instructions, Appendix 3, for additional award administration information.

Any assistance instrument awarded under this Program Announcement/Funding Opportunity will
be governed by the award terms and conditions, which conform to DoD’s implementation of the
Office of Management and Budget (OMB) circulars applicable to financial assistance. Terms
and conditions of new awards made after December 26, 2014 may include revisions to reflect
DoD implementation of new OMB guidance in the Code of Federal Regulations, Title 2,
Part 200, “Uniform Administrative Requirements, Cost Principles, and Audit Requirements for
Federal Awards” (2 CFR part 200).

B. Administrative Requirements

Refer to the General Application Instructions, Appendix 3, for general information regarding
administrative requirements.

C. National Policy Requirements

Refer to the General Application Instructions, Appendix 4, for general information regarding
national policy requirements.

D. Reporting

Refer to the General Application Instructions, Appendix 3, Section I, for general information on
reporting requirements.
E. Award Transfers

The institution transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

Refer to the General Application Instructions, Appendix 3, Section M, for general information on organization or PI changes.

VI. AGENCY CONTACTS

A. CDMRP Help Desk

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

   Phone: 301-682-5507
   Email: help@eBRAP.org

B. Grants.gov Contact Center

Questions related to application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

   Phone: 800-518-4726
   Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
## VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Upload Order</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF-424 (R&amp;R) Application for Federal Assistance</td>
<td>Complete form as instructed.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Attachments Form

1. Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf.”
5. Statement of Work: Upload as Attachment 5 with file name “SOW.pdf.”
6. Surveys, Questionnaires, and Other Data Collection Instructions: Upload as Attachment 6 with file name “Surveys.pdf,” if applicable.
8. IND/IDE Documentation: Upload as Attachment 8 with file name “IND-IDE.pdf.”

### Research & Related Senior/Key Person Profile (Expanded)

Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.

Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.

Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.

Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.

### Research & Related Budget

Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.

### Project/Performance Site Location(s) Form

Complete form as instructed.

### R & R Subaward Budget Attachment(s) Form

Complete form as instructed.